Form D · Pharmaceuticals

Cingulate Therapeutics

Kansas City, KS · CIK 0001593151

Offering snapshot reported Jun 29, 2020 · SEC filing

Reported sold
$26.2M
Indefinite offering
Investors reported
203
Form D · investor count
Minimum accepted
$100K
Reported outside-investor minimum
First sale
Nov 14, 2013
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$13.1M$26.2MJul 11, 2018: $15,600,000.00Jul 11, 2018Jul 3, 2019: $19,200,000.00Jul 3, 2019Jun 29, 2020: $26,200,000.00Jun 29, 2020

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$19,200,000 → $26,200,000
  • Reported investors156 → 203

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 29, 2020Amendment$26,200,000$7,000,000vs Jul 3, 2019203SEC filing
Jul 3, 2019Amendment$19,200,000$3,600,000vs Jul 11, 2018156SEC filing
Jul 11, 2018Initial$15,600,000No comparison133SEC filing
Jan 16, 2018Amendment$6,800,000$3,700,000vs May 2, 2017116SEC filing
May 2, 2017Amendment$3,100,000$3,025,000vs Jan 19, 201665SEC filing
Jan 19, 2016Amendment$75,000$0vs Nov 27, 20132SEC filing
Nov 27, 2013Initial$75,000No comparison2SEC filing

Offering details

Securities
Equity, Debt, Option to acquire, Security to be acquired, Other
Exemptions
06b, 4a5
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-316588
Membership Units, Profits Interest Units

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
NONENone

Source: Form D, filed Jun 29, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Matthew N Brams Director, Executive
Jeff Conroy Director
Patrick J Gallagher Director
Craig Steven Gilgallon Executive
Jeff Hargroves Director
Laurie A Myers Executive
Shane J Schaffer Director, Executive
Raul R Silva Executive
Arthur B Straughn Director
Craig Stephen Tashjy Executive
Louis George Van Horn Executive
Peter J Werth Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
1901 W. 47th Place Third Floor
Kansas City, KS, 66205